CAS 1042385-75-0

Dacomitinib hydrate

Description:

Dacomitinib hydrate is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC). It functions by irreversibly inhibiting the epidermal growth factor receptor (EGFR) and other related kinases, thereby disrupting signaling pathways that promote tumor growth and survival. The substance is characterized by its molecular formula, which includes a hydrate component, indicating the presence of water molecules in its crystalline structure. Dacomitinib exhibits high oral bioavailability and is typically administered in tablet form. Its pharmacokinetics involve extensive metabolism, primarily via the liver, and it has a relatively long half-life, allowing for once-daily dosing. Common side effects associated with dacomitinib include diarrhea, rash, and decreased appetite, reflecting its mechanism of action and impact on normal epithelial tissues. As with many targeted therapies, monitoring for adverse effects and drug interactions is essential during treatment. Overall, dacomitinib hydrate represents a significant advancement in targeted cancer therapy, offering a treatment option for patients with specific genetic mutations in their tumors.

Formula: C₂₄H₂₇ClFN₅O₃

Synonyms:

• PF-00299804(dacomitinib)
• (E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide hydrate
• PF-00299804-3
• Dacomitinib hydrate
• Dacomitinib hydrate (PF-00299804
• DACOMITINIB MONHYDRAT
• (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide,hydrate
• Dacomitinib (PF-00299804) Hydrate
• (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide hydrate (1:1)
• (2E)-N-(4-(3-Chloro-4-fluorophenyl)amino)7-methoxyquinazolin-6-yl)4-(piperidin-1-yl)but-2-enamide monohydrate
• Dacomitinib Monhydrate
• PF-804

PF-00299804

CAS: 1042385-75-0

Formula: C₂₄H₂₇ClFN₅O₃

Purity: 99%

Color and Shape: Solid

Molecular weight: 487.9543

Ref: IN-DA008XB8

Dacomitinib hydrate

CAS: 1042385-75-0

Dacomitinib hydrate

Purity: ≥98%

Molecular weight: 487.96g/mol

Ref: 54-BUP15540

Dacomitinib hydrate

CAS: 1042385-75-0

Dacomitinib hydrate (PF 299804) is a highly selective and second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor family of

Formula: C₂₄H₂₇ClFN₅O₃

Purity: 99.52%

Color and Shape: Solid

Molecular weight: 487.96

Ref: TM-T19965

Dacomitinib Hydrate

CAS: 1042385-75-0

Formula: C₂₄H₂₅ClFN₅O₂H₂O

Molecular weight: 469.95 : 18.02

Ref: ST-EA-CP-D72008